FDA — authorised 18 June 1993
- Application: NDA020134
- Marketing authorisation holder: Q BIOMED
- Local brand name: METASTRON
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 STRONTIUM CHLORIDE SR 89 in United States
FDA authorised STRONTIUM CHLORIDE SR 89 on 18 June 1993
Marketing authorisations
FDA — authorised 6 January 2003
- Application: ANDA075941
- Marketing authorisation holder: Q BIOMED
- Local brand name: STRONTIUM CHLORIDE SR-89
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
STRONTIUM CHLORIDE SR 89 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is STRONTIUM CHLORIDE SR 89 approved in United States?
Yes. FDA authorised it on 18 June 1993; FDA authorised it on 6 January 2003; FDA has authorised it.
Who is the marketing authorisation holder for STRONTIUM CHLORIDE SR 89 in United States?
Q BIOMED holds the US marketing authorisation.